Molecular testing in fine-needle aspiration (FNA) has profoundly altered the management of thyroid cancer, particularly in cases where cytology alone is inconclusive. The Bethesda System for analyzing thyroid histopathology and Thyroid Imaging Reporting and Data System (TIRADS) for evaluating thyroid ultrasounds provide frameworks for risk stratification, but indeterminate categories remain clinically challenging when deciding whether surgery would be appropriate. Incorporating molecular markers such as BRAF, RAS, RET/PTC, and PAX8/PPARγ improves diagnostic accuracy in these scenarios. Commercially available next-generation sequencing assays detect a broad range of alterations, refining risk assessment for indeterminate nodules. This integration reduces unnecessary surgeries and allows clinicians to offer more tailored management strategies. These molecular testing strategies represent a powerful tool in optimizing thyroid nodule evaluation and management.